Trastuzumab plus tamoxifen: anti-proliferative and molecular interactions in breast carcinoma. (Q45023673)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15319565%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

title

Trastuzumab plus tamoxifen: anti-proliferative and molecular interactions in breast carcinoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15319565%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

1 reference

1 reference

molecular interaction

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15319565%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

author name string

Santiago Ropero

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15319565%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Alejandro Vázquez-Martín

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15319565%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Sagrario Montero

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15319565%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Hernán Cortés-Funes

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15319565%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Ramon Colomer

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15319565%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

language of work or name

English

0 references

publication date

1 July 2004

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15319565%20AND%20SRC:MED&resulttype=core&format=json

Breast Cancer Research and Treatment

31 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15319565%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

volume

86

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15319565%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15319565%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

page(s)

125-137

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15319565%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1023/b:brea.0000032981.20384.c6

31 December 2019

exact match

0 references

cites work

In vitro and in vivo anti-tumour effects of a humanised monoclonal antibody against c-erbB-2 product

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000032981.20384.C6

Specificity within the EGF family/ErbB receptor family signaling network

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000032981.20384.C6

7 January 2021

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000032981.20384.C6

7 January 2021

The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy.

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000032981.20384.C6

7 January 2021

Overexpression of ErbB2 in cancer and ErbB2-targeting strategies

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000032981.20384.C6

7 January 2021

Anti-p185HER2 monoclonal antibodies: biological properties and potential for immunotherapy.

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000032981.20384.C6

7 January 2021

Agonistic antibodies stimulate the kinase encoded by the neu protooncogene in living cells but the oncogenic mutant is constitutively active

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000032981.20384.C6

7 January 2021

Humanization of an anti-p185HER2 antibody for human cancer therapy

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000032981.20384.C6

7 January 2021

Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000032981.20384.C6

7 January 2021

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000032981.20384.C6

7 January 2021

The predictive value of estrogen and progesterone receptors' concentrations on the clinical behavior of breast cancer in women. Clinical correlation on 547 patients

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000032981.20384.C6

7 January 2021

Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000032981.20384.C6

7 January 2021

William L. McGuire Memorial Symposium. The role of erbB2 signal transduction pathways in human breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000032981.20384.C6

7 January 2021

Enhanced anti-proliferative activity of the combination of tamoxifen plus HER-2-neu antibody

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000032981.20384.C6

7 January 2021

Effects of gamma-linolenic acid and oleic acid on paclitaxel cytotoxicity in human breast cancer cells

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000032981.20384.C6

7 January 2021

Synergistic interaction between vinorelbine and gamma-linolenic acid in breast cancer cells

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000032981.20384.C6

7 January 2021

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000032981.20384.C6

7 January 2021

Acquired antiestrogen resistance in MCF-7 human breast cancer sublines is not accomplished by altered expression of receptors in the ErbB-family.

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000032981.20384.C6

7 January 2021

The pure antiestrogen ICI 182780 is more effective in the induction of apoptosis and down regulation of BCL-2 than tamoxifen in MCF-7 cells

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000032981.20384.C6

7 January 2021

Regulation of estrogen receptor concentration and activity by an erbB/HER ligand in breast carcinoma cell lines

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000032981.20384.C6

7 January 2021

Anti-HER2 antibody enhances the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both oestrogen receptors and HER2.

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000032981.20384.C6

7 January 2021

Tamoxifen up-regulates c-erbB-2 expression in oestrogen-responsive breast cancer cells in vitro

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000032981.20384.C6

7 January 2021

Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000032981.20384.C6

7 January 2021

Bidirectional interactions between the estrogen receptor and the cerbB-2 signaling pathways: heregulin inhibits estrogenic effects in breast cancer cells

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000032981.20384.C6

7 January 2021